<code id='851EAC43DE'></code><style id='851EAC43DE'></style>
    • <acronym id='851EAC43DE'></acronym>
      <center id='851EAC43DE'><center id='851EAC43DE'><tfoot id='851EAC43DE'></tfoot></center><abbr id='851EAC43DE'><dir id='851EAC43DE'><tfoot id='851EAC43DE'></tfoot><noframes id='851EAC43DE'>

    • <optgroup id='851EAC43DE'><strike id='851EAC43DE'><sup id='851EAC43DE'></sup></strike><code id='851EAC43DE'></code></optgroup>
        1. <b id='851EAC43DE'><label id='851EAC43DE'><select id='851EAC43DE'><dt id='851EAC43DE'><span id='851EAC43DE'></span></dt></select></label></b><u id='851EAC43DE'></u>
          <i id='851EAC43DE'><strike id='851EAC43DE'><tt id='851EAC43DE'><pre id='851EAC43DE'></pre></tt></strike></i>

          focus

          focus

          author:focus    Page View:341
          ASH19 CAR-T
          Victor Segura Ibarra and Rita Serda, Ph.D., NCI, NIH

          The Food and Drug Administration on Wednesday approved a futuristic new approach to treating cancer, clearing a Novartis therapy that has produced unprecedented results in patients with a rare and deadly cancer. The price tag: $475,000 for a course of treatment.

          That sounds staggering to many patients — but it’s far less than analysts expected.

          advertisement

          The therapy, called a CAR-T, is made by harvesting patients’ white blood cells and rewiring them to home in on tumors. Novartis’s product is the first CAR-T therapy to come before the FDA, leading a pack of novel treatments that promise to change the standard of care for certain aggressive blood cancers.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          How to save PrEP access — and even expand it
          How to save PrEP access — and even expand it

          UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

          read more
          ‘Oppenheimer’ and the risks of AI in health care
          ‘Oppenheimer’ and the risks of AI in health care

          APAllgreatstorieshavecomplicatedendings.Butthatdoesn’tmeantheycan’toffersimpleandinstructivelessons.

          read more
          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more

          Lawsuit alleges UnitedHealth Group unit illegally denied claims

          JimMone/APTheU.S.DepartmentofLaborclaimsinanewlawsuitthataUnitedHealthGroupunitillegallyrejectedemer